Sunshine Biopharma

Sunshine’s Adva-27a study results

Monday, July 11, 2011

Sunshine Biopharma, a development stage pharmaceutical company, has completed a detailed cytotoxicity study of its lead compound, Adva-27a, in MCF-7/MDR, a Multidrug Resistant Breast Cancer cell line.  Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.  The results showed that Adva-27a is 16 times more effective at killing Multidrug Resistant Breast Cancer cells than Etoposide, the current commonly used drug.  Data generated by the study revealed that Adva-27a is unaffected by the molecular machinery which are responsible for making cancer cells resistant to drugs.

[Read More]

Sunshine Biopharma to conduct trial for Jewish General Hospital

Friday, June 17, 2011

Sunshine Biopharma, a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, has executed an agreement with The Jewish General Hospital, one of McGill University’s Hospital Centers, to conduct the necessary R&D to advance Sunshine’s lead compound, Adva-27a, through the various stages of pre-clinical studies and phase I clinical trials.

[Read More]